Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Wilms Tumor 3Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Beckwith-Wiedemann Syndrome 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4Vincristine 3Specimen Handling 3Irinotecan 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2ensartinib 2Temozolomide 2Radiotherapy 2temsirolimus 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1liposomal doxorubicin 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1erdafitinib 1cabozantinib 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Dactinomycin × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡